Tag: Johnson & Johnson

First Atrial Fibrillation Patient Treated In Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation Catheter

IRVINE, Calif., Feb. 4, 2019 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study** which evaluates the company’s QDOT MICRO Radiofrequency […]

Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention

New Brunswick, NJ, January 17, 2019 — Johnson & Johnson (NYSE: JNJ) today announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with Apple Inc. to investigate whether a new heart health program using an app from Johnson […]

BIOSENSE WEBSTER ANNOUNCES FIRST PATIENTS ENROLLED IN POST-MARKET APPROVAL STUDY FOR ITS NOVEL TAG-INDEX GUIDED SOFTWARE

IRVINE, Calif., SEPTEMBER 26 – Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has received approval from the U.S. Food and Drug Administration (FDA) for its VISITAG SURPOINT External Processing Unit and enrollment has begun […]

Johnson & Johnson Medical Devices Companies Signals Commitment to Stroke Treatment With the Announcement of New Neurovascular Business

NICE, France, September 7, 2017 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the European Society of Minimally Invasive Neurological Therapy (ESMINT) 9th Annual Meeting. CERENOVUS, a name derived from the Latin words for ‘new’ and ‘brain’, will focus on delivering innovative therapies for hemorrhagic […]